Connor, Clark & Lunn Investment Management (CC&L)
KRTX

Connor, Clark & Lunn Investment Management (CC&L)’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-42,289
Closed -$13.4M – 1751
2023
Q4 		$13.4M Sell
42,289
-10,401
-20% -$2.02M 0.06% 238
2023
Q3 		$8.91M Buy
52,690
+10,779
+26% +$2.03M 0.05% 272
2023
Q2 		$9.09M Buy
41,911
+2,171
+5% +$465K 0.05% 270
2023
Q1 		$7.22M Buy
39,740
+4,094
+11% +$783K 0.04% 303
2022
Q4 		$7M Sell
35,646
-3,947
-10% -$846K 0.04% 287
2022
Q3 		$8.91M Buy
+39,593
New +$8.01M 0.06% 220

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s KRTX Position: Q1 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 42,289 shares — an estimated $13.4M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in KRTX in Q3 2022 and held it in 6 quarters. The position peaked at $13.4M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 42,289 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $13.4M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2022 and held it in 6 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Karuna Therapeutics, Inc. Common Stock position peaked at $13.4M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2024, filed 9 May 2024.